ROBIN HOWARD W (President & CEO) sold 17.4% of their position (11.83K shares) of NEKTAR THERAPEUTICS on the open market
Open‑market sale worth $431.0K — a significant reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−1.92K
Price / share
$32.37
Trade value
$62.25K
% of position
Common Stock
Shares
−1.50K
Price / share
$33.54
Trade value
$50.18K
% of position
Common Stock
Shares
−613.00
Price / share
$34.40
Trade value
$21.09K
% of position
Common Stock
Shares
−1.13K
Price / share
$35.80
Trade value
$40.60K
% of position
Common Stock
Shares
−3.30K
Price / share
$37.87
Trade value
$125.12K
% of position
Common Stock
Shares
−2.23K
Price / share
$38.82
Trade value
$86.41K
% of position
Common Stock
Shares
−1.14K
Price / share
$39.89
Trade value
$45.32K
% of position
Net shares
−11.83K
Net value
-$430.96K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 9/4/2025 | S · Sale | −1.92K | $32.37 | $62.25K | 2.8% | 67.84K | 65.92K |
| Common Stock Direct | 9/4/2025 | S · Sale | −1.50K | $33.54 | $50.18K | 2.3% | 65.92K | 64.42K |
| Common Stock Direct | 9/4/2025 | S · Sale | −613.00 | $34.40 | $21.09K | 1.0% | 64.42K | 63.81K |
| Common Stock Direct | 9/4/2025 | S · Sale | −1.13K | $35.80 | $40.60K | 1.8% | 63.81K | 62.67K |
| Common Stock Direct | 9/5/2025 | S · Sale | −3.30K | $37.87 | $125.12K | 5.3% | 62.67K | 59.37K |
| Common Stock Direct | 9/5/2025 | S · Sale | −2.23K | $38.82 | $86.41K | 3.7% | 59.37K | 57.14K |
| Common Stock Direct | 9/5/2025 | S · Sale | −1.14K | $39.89 | $45.32K | 2.0% | 57.14K | 56.01K |
| Total | −11.83K | -$430.96K | ||||||
Common Stock
Indirect| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 28.00 | Indirect |
| Total | 28.00 | 28.00 indirect |